New drug combo targets Hard-to-Treat HER2 cancers
NCT ID NCT07512583
First seen Apr 06, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This study tests a combination of two experimental drugs, TQB2930 and TQB2102, both designed to attack cancer cells that have a protein called HER2. The trial enrolls about 178 adults with advanced solid tumors that express HER2 and have not responded to standard treatments. The goal is to find the best dose and see if the combination can shrink tumors or slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University Cancer Institute&Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQB2930 (a bispecific antibody) and TQB2102 (an antibody-drug conjugate), both targeting HER2
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced HER2-positive solid tumors that have not responded to other therapies.
What could go wrong
This is an early-phase trial (Phase Ib/II) with a small number of participants, so the benefits and risks are not yet well understood. The combination may cause significant side effects or fail to shrink tumors.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.